Streetwise Reports' Article Archives — Current Month (12)
AI Cancer Discovery Shows Breakthrough in Brain-Targeting Treatment (10/20/2025)
Rakovina Therapeutics Inc. (RKV:TSX.V) is set to unveil new preclinical data from its AI-driven ATR inhibitor program at a major international cancer conference in Boston. The findings highlight strong efficacy and blood-brain barrier permeability, a potential breakthrough for hard-to-treat tumors and brain metastases.
Cleantech Co. Advances Antimicrobial Wound Care Breakthrough (10/17/2025)
Cleantech innovation company BioLargo Inc. (BLGO:OTCQX) announced that subsidiary Clyra Medical Technologies is making significant strides. Read why one analyst says the technology is on "the cusp of commercialization."
Biopharma's New MASH Drug Has Two MOAs (10/15/2025)
Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, noted an H.C. Wainwright & Co. report.
Life Sciences Co. Reports Strong Survival Data (10/13/2025)
OS Therapies Inc.'s (OSTX:NYSEAMERICAN) trial results are for its new immunotherapy in fully resected pulmonary metastatic osteosarcoma, noted a D. Boral Capital report.
Healthcare Tech Firm Finds Big U.S. Opportunity (10/09/2025)
Healthcare data firm OneMedNet Corporation (Nasdaq: ONMD) partners with Palantir Technologies Inc. (PLTR:NASDAQ) to analyze over 5 billion claims and 131 million exams, unlocking a possible massive U.S. breakthrough in AI-driven research.
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease (10/09/2025)
Lexeo Therapeutics Inc. (LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases.
Biotech Firm Uncovers Breakthrough Gene Therapy in New York (10/09/2025)
Lexeo Therapeutics Inc. (LXEO:NASDAQ) advanced its LX2006 program after new FDA feedback supported an accelerated approval path. Read how interim data showed strong cardiac and neurological improvements, prompting bullish analyst upgrades.
Therapeutics Company Advances Gene Therapy Breakthrough (10/09/2025)
In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. (LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval.
New Drug for Duchenne Muscular Dystrophy Nears Potential Approval (10/06/2025)
Capricor Therapeutics Inc. (CAPR:NASDAQ) could receive a PDUFA date for its cell therapy as early as spring 2026 if it follows the FDA-outlined path forward, noted an Alliance Global Partners report.
Clean Tech Co.'s 'Forever Chemical' Solution Is a PFAS Breakthrough (10/02/2025)
Clean technology company BioLargo Inc. (BLGO:OTCQX) announced compelling new findings about its proprietary Aqueous Electrostatic Concentration (AEC) "forever chemicals" solution. Read to discover why one expert thinks the breakthrough is important to the company's future.
Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy (10/01/2025)
Capricor Therapeutics Inc. (CAPR:NASDAQ) reached agreement with the FDA to include HOPE-3 trial data in its BLA for Deramiocel, its cell therapy for Duchenne muscular dystrophy. With topline results due in Q4, learn how the company is advancing one of the few late-stage programs in this high-need rare disease space.
Biotech Battles FDA, Target Price Shows Potential 90% Gains (10/01/2025)
Capricor Therapeutics Inc. (CAPR:NASDAQ) has recently been involved in a "tug-of-war with the FDA." Read on to see why one Roth analyst still rates this stock as a Buy.
More Archives
2025Sep Aug Jul Jun May Apr Mar Feb Jan
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
